Akanda Corp (AKAN)
Company Info
CA00971M1068
Mar 15, 2022
Highlights
$2.94M
-$524.76
$477.01K
-$139.25K
-$2.04M
$0.93 - $13.81
2.03%
1.77
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Akanda Corp, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Akanda Corp (AKAN) returned -24.79% year-to-date (YTD) and -83.12% over the past 12 months.
AKAN
-24.79%
9.39%
-24.12%
-83.12%
N/A
N/A
^GSPC (Benchmark)
-3.70%
13.67%
-5.18%
9.18%
14.14%
10.43%
Monthly Returns
The table below presents the monthly returns of AKAN, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025 | 0.63% | 4.97% | -18.34% | -3.62% | -9.53% | -24.79% | |||||||
2024 | -11.45% | -34.15% | -54.60% | -20.24% | -30.11% | -11.15% | -35.06% | -18.67% | -5.74% | -37.22% | 21.19% | -8.57% | -95.46% |
2023 | 111.41% | -39.37% | -49.20% | 5.12% | -28.43% | 1.37% | -16.22% | -8.02% | -7.05% | -19.90% | 15.40% | -10.11% | -70.44% |
2022 | -24.38% | 6.93% | -88.51% | -16.97% | 19.77% | -21.44% | -39.60% | -40.52% | -19.61% | -32.30% | -98.58% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of AKAN is 13, meaning it’s performing worse than 87% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Akanda Corp (AKAN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Akanda Corp. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Akanda Corp was 99.99%, occurring on Apr 10, 2025. The portfolio has not yet recovered.
The current Akanda Corp drawdown is 99.99%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
---|---|---|---|---|---|---|
-99.99% | Apr 22, 2022 | 745 | Apr 10, 2025 | — | — | — |
-32.79% | Mar 17, 2022 | 2 | Mar 18, 2022 | 22 | Apr 20, 2022 | 24 |
Volatility
Volatility Chart
The current Akanda Corp volatility is 19.37%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Akanda Corp over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Akanda Corp, comparing actual results with analytics estimates.
Valuation
The Valuation section provides an overview of how Akanda Corp is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for AKAN relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, AKAN has a P/S ratio of 1.2. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for AKAN in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, AKAN has a P/B value of 0.6. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
TTM | |
---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |